Company name: HemoShear LLC.
Industry: biotechnology.
Location: Charlottesville, Virginia.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Solution/product: HemoShear provides pharmaceutical and biotechnology companies with human and animal cell-based systems that replicate organ systems and diseases to enable and improve drug discovery and development.
Money raised: The recent close of a $4 million series C marks the fourth round of equity for the company and brings its total capital raised to $13 million.
How it will be used: HemoShear will move to a larger lab next year and expand its science and business staff. “Our customer base and revenues are growing rapidly,” CEO Jim Powers said in a statement.
Investors: unknown.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Management team: Powers came from PRA International, a former niche service provider that grew into a global clinical trials management organization and went public in 2004. Chief financial officer Brian Campbell is a former executive of several companies in the aviation sector.
Market opportunity: As the pharmaceutical industry looks for new ways to speed up drug discovery and development, the global market for drug discovery technologies and products is expected to grow from $41 billion in 2012 to $79 billion in 2017, according to a market analysis from research firm Global Information Inc.
